Skip to main content

Acrivon Therapeutics, Inc.

ACRV
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001781174

In the last 90 days, Acrivon Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 46 institutions reported holding it in 13F filings for Q2 2026, worth $38.1M in total; no superinvestor holds it.

Superinvestors holding ACRV, Q2 2026

See all superinvestors

No superinvestor reported holding ACRV in Q2 2026.